IDEXX Laboratories, Inc.
IDXX
$557.02
+3.02%
Idexx Laboratories develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock, operating in the medical diagnostics and research industry. As a market leader in veterinary diagnostics, the company distinguishes itself through its comprehensive portfolio of in-clinic test kits, benchtop analyzers, reference lab services, and practice management software. The current investor narrative centers on resilient demand driven by higher clinical visits and diagnostic frequency, as evidenced by the company's raised guidance following strong Q1 2026 results. Attention is also focused on margin expansion and the sustainability of double-digit revenue growth amid a mixed macroeconomic backdrop.…
IDXX
IDEXX Laboratories, Inc.
$557.02
Related headlines
Investment Opinion: Should I buy IDXX Today?
Rating: Hold. IDXX is a high-quality growth company with strong fundamentals, but its premium valuation and technical weakness suggest limited near-term upside. The analyst consensus is bullish with an average target of ~$880, implying 58% upside, but the stock's downtrend and high beta warrant caution. A Hold rating balances the attractive long-term growth story with the risk of further multiple compression.
Supporting Evidence: IDXX's revenue growth accelerated to 14.3% YoY in Q1 2026, with net margins expanding to 24.4% and ROE at 66%. Free cash flow of $1.08B TTM supports aggressive share repurchases. The forward P/E of 33.7x is below its five-year average of ~45x, suggesting valuation has compressed. However, the trailing P/E of 51.4x is still well above the industry average of 22.0x. The implied analyst target of $880 offers significant upside, but the stock's 22% decline over six months indicates that the market is already pricing in risks.
Risks & Conditions: The Hold rating would upgrade to Buy if the stock breaks above $570 (recent consolidation zone) with volume, or if forward P/E compresses below 30x. It would downgrade to Sell if revenue growth decelerates below 10% or if gross margins fall below 60%. The biggest risks are valuation compression and growth deceleration. Overall, IDXX is fairly valued relative to its growth rate (PEG ratio of 2.3x), but overvalued on an absolute basis compared to the market. Investors should wait for a better entry point or confirmation of the uptrend.
Sign up to view all
IDXX 12-Month Price Forecast
IDXX's fundamentals are strong, with accelerating revenue, expanding margins, and excellent cash flow. However, the stock's technical downtrend and premium valuation create a mixed outlook. The base case of gradual recovery is most likely, with a 50% probability. The bull case requires sustained growth and multiple expansion, while the bear case hinges on growth deceleration. The neutral stance reflects the tension between quality fundamentals and unfavorable technicals. An upgrade to bullish would require a break above $570 and confirmation of sustained growth; a downgrade to bearish would follow a growth miss or margin compression.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IDEXX Laboratories, Inc.'s 12-month outlook, with a consensus price target around $708.43 and implied upside of +27.2% versus the current price.
Average Target
$708.43
0 analysts
Implied Upside
+27.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$470 - $805
Analyst target range
Five analysts cover IDXX, with a consensus leaning bullish: two Buy/Overweight, two Neutral, and no Sell ratings. The average target price is not explicitly provided, but using the estimated EPS average of $26.10 and forward P/E of 33.7x implies a price target of approximately $880, representing 58% upside from the current $557.02. This suggests strong bullish conviction among analysts, though the small coverage base limits the robustness of the consensus. The target range, implied by EPS estimates of $25.81 to $26.34, corresponds to a price range of $870 to $888, a narrow spread of about 2%. This tight range indicates high conviction among analysts, with the high target assuming continued margin expansion and revenue acceleration, while the low target still implies significant upside. Recent ratings actions have been stable: UBS maintained Neutral, Stifel and BTIG reiterated Buy, and Barclays and Morgan Stanley maintained Overweight. The lack of downgrades despite the stock's decline suggests analysts view the pullback as a buying opportunity, though the limited number of analysts means investors should seek additional perspectives.
Bulls vs Bears: IDXX Investment Factors
IDXX presents a compelling bull case built on accelerating revenue growth (14.3% YoY), expanding margins (net margin 24.4%), exceptional ROE (66%), and strong free cash flow ($1.08B TTM). The company's dominant position in veterinary diagnostics provides a durable competitive advantage. However, the bear case centers on a premium valuation (trailing P/E 51.4x vs. industry 22.0x), a sustained downtrend (-22.1% over six months), and high beta (1.55) that amplifies downside. The single most important tension is whether IDXX can sustain its double-digit revenue growth and margin expansion to justify its premium multiple. If growth remains robust, the stock could re-rate higher; if it decelerates, the valuation could compress significantly. Currently, the bull case has stronger evidence given the raised guidance and strong Q1 results, but the technical weakness and valuation premium warrant caution.
Bullish
- Strong Revenue Acceleration: Q1 2026 revenue grew 14.3% YoY to $1.141B, accelerating from 9.4% in Q4 2025 and 13.4% in Q3 2025, driven by higher clinical visits and diagnostic frequency. This trend supports the company's raised guidance and suggests resilient demand.
- Expanding Profit Margins: Gross margin expanded to 63.4% in Q1 2026 from 60.3% in Q4 2025, while net margin reached 24.4%, up from 22.8%. Operating margin of 31.8% is among the highest in diagnostics, reflecting strong operational leverage.
- Exceptional ROE and Cash Flow: ROE stands at 66.0%, indicating highly efficient use of equity. Free cash flow TTM is $1.08B, providing ample capacity for share repurchases ($351M in Q1) and internal investments, with a debt-to-equity ratio of only 0.67.
- Analyst Upside Potential: With a forward P/E of 33.7x and estimated EPS of $26.10, the implied analyst target is ~$880, representing 58% upside from the current $557.02. The consensus is bullish with 2 Buy/Overweight and 2 Neutral ratings, and no Sell.
Bearish
- Premium Valuation vs. Peers: Trailing P/E of 51.4x is 134% above the industry average of 22.0x. Even the forward P/E of 33.7x is elevated, leaving little room for error if growth decelerates or margins compress.
- Sustained Downtrend and Underperformance: The stock has declined 22.1% over the past six months and is down 16.9% YTD. Relative strength vs. S&P 500 is -31.3% over six months and -15.6% over one year, indicating persistent selling pressure.
- High Beta Amplifies Downside Risk: With a beta of 1.55, IDXX is 55% more volatile than the market. In a broad market sell-off, the stock could decline significantly more than the index, as seen in the 22% drop over six months.
- Growth Deceleration Risk: While Q1 revenue growth accelerated to 14.3%, comps will become more challenging. If clinical visit growth normalizes or diagnostic frequency plateaus, revenue growth could slow, pressuring the premium valuation.
IDXX Technical Analysis
IDXX is in a sustained downtrend over the past six months, with the stock declining 22.1% in that period and currently trading at $557.02, which is 72.4% of its 52-week range ($506.91–$769.98). The 1-year price change of +5.8% masks significant weakness since the start of 2026, as the stock has fallen 16.9% year-to-date. The price sits well below the midpoint of the 52-week range, suggesting bearish sentiment and potential value opportunity if fundamentals support a recovery, though the trend remains negative. Short-term momentum is mixed: the 1-month change is -2.3%, while the 3-month change is -2.3%, indicating a deceleration in the pace of decline compared to the 6-month drop of -22.1%. This divergence could signal that selling pressure is exhausting and a base may be forming, but the lack of positive momentum suggests caution. The relative strength versus the S&P 500 is deeply negative across all timeframes, with 1-year relative strength of -15.6% and 6-month relative strength of -31.3%, confirming persistent underperformance. The 52-week low of $506.91 provides key support, while the 52-week high of $769.98 is the primary resistance. A breakout above $570 (recent consolidation zone) could signal a short-term reversal, while a breakdown below $507 would likely accelerate losses. Beta of 1.55 indicates the stock is 55% more volatile than the market, amplifying both upside and downside moves, which is critical for risk management.
Beta
1.55
1.55x market volatility
Max Drawdown
-31.3%
Largest decline past year
52-Week Range
$507-$770
Price range past year
Annual Return
+5.8%
Cumulative gain past year
| Period | IDXX Return | S&P 500 |
|---|---|---|
| 1m | -2.3% | +0.6% |
| 3m | -2.3% | +6.3% |
| 6m | -22.1% | +9.1% |
| 1y | +5.8% | +20.9% |
| ytd | -16.9% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IDXX Fundamental Analysis
Revenue growth remains robust, with Q1 2026 revenue of $1.141 billion growing 14.3% year-over-year, accelerating from the 9.4% growth in Q4 2025 and 13.4% in Q3 2025. The trailing twelve-month revenue reached approximately $4.45 billion, driven by strong product sales ($666 million in Q1) and service revenue ($475 million). The growth trajectory is supported by increased clinical visits and diagnostic frequency, as highlighted in the company's raised guidance. However, the pace of growth may moderate as comps become more challenging, but the current trend is clearly positive. Profitability is excellent, with Q1 2026 net income of $278.4 million and a net margin of 24.4%, up from 22.8% in Q4 2025. Gross margin expanded to 63.4% in Q1 from 60.3% in Q4 2025, reflecting operational leverage and pricing power. Operating margin of 31.8% is among the highest in the diagnostics industry, indicating efficient cost management. The company has been consistently profitable with expanding margins, a key positive for the investment case. The balance sheet is healthy: debt-to-equity of 0.67 is moderate, and the current ratio of 1.17 suggests adequate liquidity. Free cash flow (TTM) of $1.08 billion provides ample capacity for internal funding and share repurchases ($351 million in Q1 2026 alone). ROE of 66.0% is exceptional, reflecting high returns on shareholder equity. The strong cash generation and low leverage reduce financial risk and support continued investment in growth.
Quarterly Revenue
$1.1B
2026-03
Revenue YoY Growth
+14.3%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IDXX Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 51.4x, while the forward P/E is 33.7x, implying the market expects significant earnings growth. The gap between trailing and forward multiples suggests that analysts anticipate a sharp acceleration in EPS, which is consistent with the company's raised guidance and strong operational momentum. Compared to the industry average P/E of 22.0x (estimated), IDXX trades at a 134% premium, reflecting its superior growth, margins, and competitive position. The premium is justified by the company's 14% revenue growth, 24% net margins, and dominant market share in veterinary diagnostics, but it leaves little room for error. Historically, IDXX's trailing P/E has ranged from 35x to 86x over the past five years. The current 51.4x is near the lower end of that range, suggesting that valuation has compressed from peak levels. This could indicate a more attractive entry point if growth remains strong, but it also reflects the market's tempered expectations after the stock's decline from its 52-week high.
PE
51.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 35x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
37.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: IDXX's premium valuation is the primary financial risk. With a trailing P/E of 51.4x, the stock is priced for perfection. Any earnings miss or guidance cut could trigger a sharp de-rating. The company carries moderate debt (debt-to-equity 0.67), but interest expense of $7.7M in Q1 is manageable relative to operating income of $362.6M. Revenue concentration in pet diagnostics is a risk if pet ownership trends reverse or competition intensifies. The company's high ROE (66%) is impressive but partly driven by leverage, which could amplify downside if earnings decline.
Market & Competitive Risks: The stock's beta of 1.55 makes it highly sensitive to macro shocks. In a rising interest rate environment, growth stocks with high multiples are particularly vulnerable to valuation compression. Competitive threats from Zoetis, Heska, and new entrants could erode market share. Regulatory risks include changes in veterinary practice standards or pet health insurance reimbursement. The stock's 22% decline over six months despite strong fundamentals suggests that market sentiment has already turned negative, potentially due to sector rotation or profit-taking.
Worst-Case Scenario: A combination of slowing revenue growth (e.g., below 10%), margin compression from competitive pricing, and a broad market downturn could drive the stock to its 52-week low of $506.91. From the current price of $557.02, this represents a downside of approximately -9%. However, if the company issues a negative guidance revision, the stock could break below that level. The historical max drawdown of -31.34% from the 52-week high of $769.98 implies a potential decline to $529, which is close to the current level. In a severe bear case, the stock could fall to $450, representing a -19% loss from current levels.
FAQ
The key risks are: 1) Valuation compression: With a trailing P/E of 51.4x, any growth disappointment could lead to a sharp de-rating. 2) Growth deceleration: Revenue growth of 14.3% may slow as comps become more challenging, pressuring the premium multiple. 3) Competitive pressure: Zoetis and other players could erode market share, though IDXX's integrated platform provides a moat. 4) Macro sensitivity: A beta of 1.55 means the stock is highly correlated with market downturns, as seen in the 22% decline over six months. 5) Limited analyst coverage: Only five analysts cover the stock, increasing the risk of consensus errors. The most severe risk is a combination of growth slowdown and market correction, which could drive the stock to $450 or lower.
The 12-month forecast is mixed. The bull case (25% probability) sees the stock reaching $700-$880, driven by sustained growth and multiple expansion. The base case (50% probability) expects a range of $550-$700 as the stock gradually recovers. The bear case (25% probability) targets $450-$550 if growth decelerates or margins compress. The analyst consensus implies a target of ~$880, representing 58% upside, but the stock's technical weakness suggests near-term caution. The most likely scenario is the base case, where IDXX trades in a range as the market digests its premium valuation. Key assumptions include revenue growth of 12-14% and stable margins. Investors should watch for the next earnings report for confirmation.
IDXX's valuation is mixed. On a trailing basis, the P/E of 51.4x is 134% above the industry average of 22x, suggesting overvaluation. However, the forward P/E of 33.7x is below its five-year average of ~45x, indicating that the stock has become cheaper relative to its own history. The PEG ratio of 2.3x, based on expected EPS growth, suggests the stock is fairly valued relative to its growth rate. The market is pricing in continued double-digit growth and margin expansion. Compared to peers, IDXX commands a premium due to its dominant market position and superior profitability. Overall, the stock is not cheap, but the premium may be justified if growth persists. Investors should monitor whether revenue growth remains above 12% to support the current multiple.
IDXX is a high-quality company with strong fundamentals, but whether it's a good buy depends on your risk tolerance and time horizon. The stock offers 58% upside to the analyst target of ~$880, but it is currently in a downtrend, down 22% over six months. The trailing P/E of 51.4x is expensive relative to the industry average of 22x, though the forward P/E of 33.7x is more reasonable. For long-term growth investors who can tolerate volatility, IDXX could be a good buy on further weakness, especially near the 52-week low of $506.91. For short-term traders, the lack of positive momentum makes it risky. A prudent approach is to wait for a confirmed breakout above $570 before initiating a position.
IDXX is better suited for long-term investment due to its strong competitive position, recurring revenue, and consistent growth. The company's dominant market share in veterinary diagnostics, high ROE (66%), and robust free cash flow ($1.08B TTM) support compounding over time. However, with a beta of 1.55 and a stock down 22% over six months, it is not ideal for short-term trading unless you have a high risk tolerance. The stock pays no dividend, so returns depend entirely on price appreciation. A minimum holding period of 3-5 years is recommended to ride out volatility and allow the growth story to materialize. For short-term traders, the lack of positive momentum and high volatility make it a risky proposition.